Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Ion Beam Applications, SA
  6. News
  7. Summary
    IBAB   BE0003766806


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ion Beam Applications : Proton Therapy contract finalized with Advocate Radiation Oncology Affiliate in Florida

10/24/2021 | 08:34am EST
Proton therapy

Louvain-La-Neuve, Belgium, October 24, 2021 -IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that its proton therapy contract with Advocate Radiation Oncology, via its affiliate SouthwestFlorida Proton, has been finalized. IBA will start to recognize revenue from the contract in 2021.

The finalization of the contract follows the announcement earlier in the year that IBAhad been selected by Advocate Radiation Oncology for its new radiation oncology center. The site will serve the greater population of Southwest Florida in a centralized location between Lee and Collier County. The contract involves the delivery of IBA's Proteus®ONE* solution including Pencil Beam Scanning (PBS), Cone Beam CT (CBCT), Philips Ambient and a fully integrated quality assurance (QA) hardware and software package from IBA Dosimetry America, Inc. Advocate Radiation Oncology expects to start treating patients by 2023.

The typical end-user price for a Proteus®ONE system with a 10-year maintenance contract ranges between 40 and 50 million US dollars.

Olivier Legrain, Chief Executive Officer of IBA, commented: "The finalization of this contract highlights the growing momentum of proton therapy in the US. As we continue to reinforce our position in the region, we are hugely excited about the future opportunity there. We look forward to attending the ASTRO meeting this weekend and engaging with further potential partners."

Arie Dosoretz, CEO of Advocate Radiation Oncology, said: "We are firmly committed to providing the cancer patients of Southwest Florida with every radiation option they need and are excited for the next steps of this critical project. IBA delivers the most innovative proton technology in the world, and our patients deserve nothing less."

*Proteus®ONE is a brand name of Proteus 235


About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About Advocate Radiation Oncology
Advocate Radiation Oncology is a locally owned practice with convenient locations in South Florida. The practice's mission is to provide compassionate health care expertise to cancer patients. Advocate Radiation Oncology is directed by a team of world-class, board-certified radiation oncologists,

For more information, please visit AdvocateRO.com.


IBA - Ion Beam Applications SA published this content on 24 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 October 2021 12:33:04 UTC.

© Publicnow 2021
11/22Iba – Transparency Notification
11/19Ion Beam Applications Secures Contract to Install Proton Therapy System
11/19IBA and the Oncology Reference Center of Aviano, Italy, sign contract to install a Prot..
11/19IBA and the Oncology Reference Center of Aviano, Italy, Sign Contract to Install a Prot..
11/18IBA and NorthStar Medical Radioisotopes Sign Contract for Rhodotron® Electron Beam Acce..
11/18NorthStar Medical Radioisotopes and IBA Sign Contract for Rhodotron? Electron Beam Acce..
11/18IBA Business Update – Third Quarter 2021
10/28IBA and TRAD Tests & Radiations announce collaboration to develop next generation radia..
10/28IBA and TRAD Tests & Radiations Announce Collaboration to Develop Next Generation Radia..
10/26IBA and RaySearch expand their partnership in proton therapy
More news
Sales 2021 312 M 352 M 352 M
Net income 2021 -1,10 M -1,24 M -1,24 M
Net cash 2021 65,0 M 73,3 M 73,3 M
P/E ratio 2021 -363x
Yield 2021 1,45%
Capitalization 422 M 478 M 476 M
EV / Sales 2021 1,14x
EV / Sales 2022 1,00x
Nbr of Employees 1 512
Free-Float 68,9%
Duration : Period :
Ion Beam Applications, SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ION BEAM APPLICATIONS, SA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 14,52 €
Average target price 16,25 €
Spread / Average Target 11,9%
EPS Revisions
Managers and Directors
Olivier Legrain Chief Executive Officer, Director & MD
Soumya Chandramouli Chief Financial Officer
Pierre Mottet Chairman
Yves Jongen Director, Chief Research Officer & MD
Marcel Miller Independent Director
Sector and Competitors